Brachytherapy and pancreatic cancer.
Advances in diagnostic and therapeutic technology have not appreciably changed the outlook of patients with pancreatic cancer. While those patients presenting with localized resectable disease have the best prognosis, local control and intra-abdominal metastases remain significant obstacles to survival. Localized chemoradiation has modestly improved median survival in localized and locally advanced disease. Patients presenting with locally advanced disease at diagnosis benefit from surgical palliation which includes biliary and gastric bypass. Intraoperative interstitial brachytherapy has been effective when utilized at laparotomy to improve local control in locally advanced disease. Advances in laparoscopic techniques have provided the ability to more accurately stage patients prior to laparotomy and perform palliative procedures without the need for laparotomy. The utilization of high-dose-rate brachytherapy has proven effective in palliating obstructive symptoms with minimal morbidity on an outpatient basis. Recent efforts have focused on preoperative chemoradiation to improve resectability in selected patients and prophylactic hepatic irradiation to reduce metastases for patients with locally advanced disease.
Bodner
W R
WR
Department of Radiation Medicine, New York Medical College, Our Lady of Mercy Medical Center, Bronx 10466, USA.
Hilaris
B S
BS
D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods*; D002986:Clinical Trials as Topic; D004307:Dose-Response Relationship, Radiation; D005544:Forecasting; D006801:Humans; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D011379:Prognosis; D011829:Radiation Dosage; D015996:Survival Rate